Skip Navigation

Heather M Wilson-Robles

Associate Professor & Dr. Fred A. and Vola N. Palmer Chair in Comparative Oncology

Send Email

Phone: (979) 845-2351

Mailstop: 4474

Department: VSCS

Photo of Wilson-Robles, Heather

Education

  • Diplomate Oncology, ACVIM 2007
  • D.V.M. Veterinary Medicine, University of Tennessee 2003
  • Major Biochemistry Biochemistry, University of Tennessee 1999

Credentials

  • DACVIM (Oncology)
  • Texas Veterinary Medical Specialty License: 0335-S

Scholarly Interests

I have two main areas of scholarly interest. The first is bench top research focusing on identification and characterization of tumor initiating cells in solid tumors with a one health perspective (i.e. tumors similarities and treatment implications across species). The second focus of my research involves clinical trials in client owned dogs with spontaneously developing tumors as a basis for informing human clinical trials. Much of this research also has a one health implication designed to streamline drugs or therapies for human trials decreasing the cost of drug approval while improving therapeutic options for canines afflicted with cancer.

Publications

Identification and evaluation of putative tumour-initiating cells in canine malignant melanoma cell lines(†).
Wilson-Robles HM, Daly M, Pfent C, Sheppard S.
Vet Comp Oncol. 2013 Feb; .
Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells.
Zhang S, Kim K, Jin UH, Pfent C, Cao H, Amendt B, Liu X, Wilson-Robles H, Safe S.
Mol Cancer Ther. 2012 Jan; 11(1):108-18.
Effect of tolfenamic acid on canine cancer cell proliferation, specificity protein (sp) transcription factors, and sp-regulated proteins in canine osteosarcoma, mammary carcinoma, and melanoma cells.
Wilson H, Chadalapaka G, Jutooru I, Sheppard S, Pfent C, Safe S.
J Vet Intern Med. 2012 Jul; 26(4):977-86.
Subcutaneous infection of a cat by Colletotrichum species.
Winter RL, Lawhon SD, Halbert ND, Levine GJ, Wilson HM, Daly MK..
J Fel Med and Surg. 2010 Oct; 12(10):828-30.
Feline alimentary lymphoma: demystifying the enigma.
Wilson HM.
Top Companion Anim Med. 2008 Nov; 23(4):177-84.
Isolation and characterisation of cancer stem cells from canine osteosarcoma.
Wilson H, Huelsmeyer M, Chun R, Young KM, Friedrichs K, Argyle DJ.
Vet J. 2008 Jan; 175(1):69-75.
Is cancer a stem cell disease? Theory, evidence and implications.
Blacking TM, Wilson H, Argyle DJ.
Vet Comp Oncol. 2007 Jun; 5(2):76-89.
Clinical signs, treatments, and outcome in cats with transitional cell carcinoma of the urinary bladder: 20 cases (1990-2004).
Wilson HM, Chun R, Larson VS, Kurzman ID, Vail DM.
J Am Vet Med Assoc. 2007 Jul; 231(1):101-6.
Predictors of outcome in dogs with subcutaneous or intramuscular hemangiosarcoma.
Shiu KB, Flory AB, Anderson CL, Wypij J, Saba C, Wilson H, Kurzman I, Chun R..
J AM VEt MEd Assoc. 2011 Feb; .
In vitro evaluation of selective inhibitors of nuclear export (SINE) drugs KPT 185 and Kpt335 against canine mammary carcinoma and transitional cell carcinoma tumor initiating cells.
Grayton, Jesse; Miller, Tasha; Dow, Stephen; Wilson-robles, Heather.
Veterinary Comparative Oncology. ; .
Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy.
O'Connor CM, Sheppard S, Hartline CA, Huls H, Johnson M, Palla SL, Maiti S, Ma W, Davis RE, Craig S, Lee DA, Champlin R, Wilson H, Cooper LJ..
Sci Rep. ; .
Developing T cell cancer immunotherapy in the dog with lymphoma.
O'Connor CM, Wilson-Robles H..
ILAR. ; 55(1):169-81.
Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells.
Mata M1, Vera JF, Gerken C, Rooney CM, Miller T, Pfent C, Wang LL, Wilson-Robles HM, Gottschalk S..
Journal of Immunotherapy. ; 37(8):407-15..
The melanoma vaccine.
HM Wilson-Robles.
Clinician's Brief. ; .
Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.
London CA, Bernabe LF, Barnard S, Kisseberth WC, Borgatti A, Henson M, Wilson H, Jensen K, Ito D, Modiano JF, Bear MD, Pennell ML, Saint-Martin JR, McCauley D, Kauffman M, Shacham S.
PLoS One. ; 9(2):e87585.
Expression of leptin and iNOS in oral melanomas in dogs.
Greene VR, Wilson H, Pfent C, Roethele J, Carwile J, Qin Y, Grimm E, Ellerhorst JA.
J Vet Intern Med. ; 27(5):1278-82.
A Comparative Oncology Study of Iniparib Defines its Pharmacokinetic Profile and Biological Activity in a Naturally-occurring Canine Cancer Model".
Corey Saba; Melissa Paoloni; Christina Mazcko; William Kisseberth; Jenna H Burton; Annette Smith; Heather Wilson-Robles; Sara Allstadt; David Vail; Carolyn Henry; Susan Lana; E.J. Ehrhart; Brad Charles; Michael Kent; Jessica Lawrence; Kristine Burgess; Antonella Borgatti; Steve Suter; Paul Woods; Ira Gordon; Patricia Vrignaud; Chand Khanna; Amy LeBlanc.
PLOS ONE. ; Plos One.
Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma
Melissa Paoloni1, Christina Mazcko1, Kimberly Selting2, Susan Lana3, Lisa Barber4, Jeffrey Phillips5, Katherine Skorupski6, David Vail7, Heather Wilson8, Barbara Biller3, Anne Avery3, Matti Kiupel9, Amy LeBlanc1, Anna Bernhardt10, Beatrice Brunkhorst10, Robert Tighe10, Chand Khanna1*.
PLOS One. ; Plos One.
Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma Following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study
Cheryl London, PhD, DVM; Heather Gardner; Tamra Mathie; Nicole Stingle; Roberta Portela; Michael Pennell; Craig Clifford; Mona Rosenberg; David Vail; Laurel Williams; Kim Cronin; Heather Wilson-Robles; Antonella Borgatti; Carolyn Henry; Dennis Bailey; Jennifer Locke; Nicole Northrup; Martin Jakubiak; Virginia Gill; Mary Kay Klein; David Ruslander; Douglas Thamm; Brenda Phillips; Gerald Post.
PLOS One. ; Plos One.


Request Update